A.M.M. has received financial support from Pfizer (formerly Wyeth), Janssen and Lilly. A.M.M. has done consultancy work for Roche Pharmaceuticals. H.R.K. has been a consultant or advisory board member with Alkermes, Lilly, Lundbeck, Otsuka, Pfizer and Roche. He is a member of the Alcohol Clinical Trials Initiative (ACTIVE) of the American Society of Clinical Psychopharmacology, which is supported by AbbVie, Ethypharm, Lilly, Lundbeck and Pfizer and has a US patent pending, entitled ‘Test for Predicting Response to Topiramate and Use of Topiramate’. L.J.H. has received financial support from Pfizer for work unrelated to the present study.
